Nimbus Therapeutics to Present New Data on Novel HPK1 Inhibitors at Upcoming Scientific Conferences

Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the presentation of new data on the company’s novel hematopoietic progenitor kinase 1 (HPK1) inhibitors at upcoming scientific conferences.

At the 32^nd EORTC-NCI-AACR Symposium, from October 24-25, 2020, Nimbus will present new in vivo data, including target engagement, tumor growth inhibition, and pharmacodynamics in two mouse syngeneic tumor models (CT26 and B16/F10).

Further, at the Society for Immunotherapy of Cancer’s (SITC) 35^th Anniversary Annual Meeting, from November 9-14, 2020, Nimbus will present new data on in vitro pharmacology and mechanism of action of the HPK1 inhibitors, including effects on T cells, B cells, dendritic cells and antigen presentation.

“Building on the data we presented at AACR earlier this year, we’re pleased to share these new results which provide further support for the anti-tumor immune activity of our small-molecule HPK1 inhibitors,” said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus. “We are progressing towards initiation of IND-enabling studies in the near future, with plans to embark upon first-in-human studies of this novel therapeutic in 2021.”

Details of the presentations are as follows:

EORTC 2020: Pre-recorded presentation with live Q&A

• Title: “A Highly Selective and Potent HPK1 Inhibitor Enhances Immune Cell Activation and Induces Robust Tumor Growth Inhibition in a Murine Syngeneic Tumor Model”
• Presentation Number: PD-046
• Date & Time: Sun., Oct. 25, 2:50 p.m. CET (9:50 a.m. ET)

SITC 2020: Live presentation

• Title: “A Highly Selective and Potent HPK1 Inhibitor Enhances Immune Cell Activation and Induces Robust Tumor Growth Inhibition in a Murine Syngeneic Tumor Model”
• Poster Number: 685
• Dates & Times: Weds., Nov. 11, 5:15 p.m. ET; Fri., Nov. 13, 4:40 p.m. ET

About Nimbus Therapeutics

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. www.nimbustx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005390/en/